TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03424005
Drug: Sacituzumab Govitecan
Normalized name: sacituzumab govitecan
DrugBank: Sacituzumab govitecan (DB12893)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sacituzumab govitecan will be administered by IV, 10 mg/kg, on Days 1 and 8 of each 21-day cycle.
Study: NCT03424005
Drug: Abemaciclib
Normalized name: Abemaciclib
DrugBank: Abemaciclib (DB12001)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Abemaciclib tablets will be administered at a dose of 150 mg twice daily by mouth on Days 1-28 of each cycle (cycle=28 days).
Study: NCT03424005
Drug: Fulvestrant
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Fulvestrant IM injection at a dose of 500 mg will be administered on Days 1 and 15 of Cycle 1, and then on Day 1 of each cycle thereafter (cycle=28 days).
Study: NCT03424005
Drug: Ribociclib (dose #1)
DrugBank: Ribociclib (DB11730)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ribociclib tablets will be administered by mouth once daily.
Study: NCT02723578
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pemetrexed 500 mg/m2 IV over 10 minutes on day 1 every 21 days
Study: NCT02723578
Drug: Erlotinib
Normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erlotinib 150 mg PO once daily on days 1-21 every 21 days
Study: NCT03424005
Drug: Inavolisib (dose #2)
Normalized name: Inavolisib
DrugBank: Inavolisib (DB15275)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inavolisib tablets will be administered by mouth once daily.
Study: NCT03424005
Drug: Trastuzumab Deruxtecan
Normalized name: Trastuzumab deruxtecan
DrugBank: Trastuzumab deruxtecan (DB14962)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Trastuzumab Deruxtecan will be administered at a dose of 5.4 mg/kg by IV infusion on Day 1 of each 21-day cycle.
Study: NCT03424005
Drug: Ribociclib (dose #2)
DrugBank: Ribociclib (DB11730)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ribociclib tablets will be administered by mouth once daily.
Study: NCT03424005
Drug: Letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Letrozole tablets will be administered at a dose of 2.5 mg once a day by mouth on Days 1-28 of each cycle (cycle = 28 days).
Study: NCT00436527
Drug: Metronidazole gel 1%
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Applied once to a test site on the right or left cheek (as determined by a randomization design)
Study: NCT00036582
Drug: Clozapine
Normalized name: Clozapine
DrugBank: Clozapine (DB00363)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01497873
Drug: Topotecan
Normalized name: Topotecan
DrugBank: Topotecan (DB01030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1.5 mg/m\^2 IV days 1, 2, 3, 4, 5 of each 21-day cycle until 6 cycle or more
Study: NCT01497873
Drug: Belotecan
Normalized name: belotecan
DrugBank: Belotecan (DB12459)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/m\^2 IV days 1, 2, 3, 4, 5 of each 21-day cycle until 6 cycle or more
Study: NCT03503227
Drug: Acetyl Salicylic acid
Normalized name: Acetyl salicylic acid specific IgE
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: daily oral low dose Acetylsalicylic acid (75 mg) : Antiplatelet agent
Study: NCT00448682
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00448682
Drug: Floxuridine
Normalized name: Floxuridine
DrugBank: Floxuridine (DB00322)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02573038
Drug: Aflibercept
Normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The patients are followed on a monthly basis until 52 weeks. Intravitreal injections of aflibercept at a dosage of 2 mg are initiated at inclusion (mandatory injection) followed by mandatory injections at week 4, week 8, week 20, week 32 and week 44. During the other visits, an injection can be performed in case of CNV activity (PRN regimen).Therefore, each patient receives between 6 and 13 injections in the whole study.
Study: NCT05458726
Drug: Osimertinib
Normalized name: Osimertinib
DrugBank: Osimertinib (DB09330)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Osimertinib or chemotherapy
Study: NCT04173364
Drug: Ropivacaine 0.5% Injectable Solution
Normalized name: ROPivacaine 0.5% injectable solution
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Injectable solution of ropivacaine 0.5%
Study: NCT04173364
Drug: Ropivacaine 0.1% Injectable Solution
Normalized name: ROPivacaine 0.1% injectable solution
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dilution of ropivacaine to the concentration of 0.1%
Study: NCT01741012
Drug: Gardasil
Normalized name: Gardasil
DrugBank: Human papillomavirus type 6 L1 capsid protein antigen (DB10299)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 ml Gardasil vaccine in single dose prefilled syringes at Visit 2, Visit 4 and Visit 6
Study: NCT02179775
Drug: propranolol
Normalized name: Propranolol
DrugBank: Propranolol (DB00571)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01955980
Drug: Budesonide
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Inhalation
Study: NCT01955980
Drug: Budesonide
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nasal Spray
Study: NCT00448682
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03618082
Drug: Administration of the lowest effective concentration of desflurane (Interventional Group)
Normalized name: Desflurane
DrugBank: Desflurane (DB01189)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administration of the lowest effective concentration of desflurane (Interventional Group) Desflurane will be administered with a targeted purpose of minimal alveolar concentration (MAC).
Study: NCT00634582
Drug: paricalcitol
Normalized name: Paricalcitol
DrugBank: Paricalcitol (DB00910)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01408576
Drug: Epratuzumab
Normalized name: Epratuzumab
DrugBank: Epratuzumab (DB04958)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg infusions delivered weekly for a total of 4 consecutive weeks (cumulative dose 2400 mg) over eight 12-week treatment cycles
Study: NCT01408576
Drug: Epratuzumab
Normalized name: Epratuzumab
DrugBank: Epratuzumab (DB04958)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1200 mg infusions delivered every other week for a total of 4 weeks (cumulative dose 2400 mg) over eight 12 week treatment cycles
Study: NCT03957590
Drug: Tislelizumab
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administrated at dose of 200 mg intravenously (IV)
Study: NCT03957590
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered as 135 mg/m² IV injection
Study: NCT03957590
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered as 25 mg/m² IV injection
Study: NCT03424005
Drug: Inavolisib (dose #1)
Normalized name: Inavolisib
DrugBank: Inavolisib (DB15275)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inavolisib tablets will be administered by mouth once daily.
Study: NCT03424005
Drug: Inavolisib
Normalized name: Inavolisib
DrugBank: Inavolisib (DB15275)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inavolisib tablets will be administered by mouth once daily.
Study: NCT00433329
Drug: Bosentan
Normalized name: Bosentan
DrugBank: Bosentan (DB00559)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral bosentan 62.5 mg BID first 4 weeks followed by 24 weeks of 125 mg BID if the 62.5 mg BID dose was well tolerated
Study: NCT00433329
Drug: Sildenafil
Normalized name: Sildenafil
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral sildenafil 20 mg TID in patients who do not reach the 6-MWT distance threshold at Week 16
Study: NCT04195698
Drug: Upadacitinib
Normalized name: Upadacitinib
DrugBank: Upadacitinib (DB15091)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Upadacitinib will be administered oral as tablet
Study: NCT02017600
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: cisplatin 70 mg/m2 on day1
Study: NCT02557594
Drug: Viread 300mg
Normalized name: Viread 300mg Tablet
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: single dose administration after 10hr fasting
Study: NCT02557594
Drug: DA-2802 319mg
Normalized name: DAS-181
DrugBank: DAS-181 (DB15313)
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose administration after 10hr fasting
Study: NCT01292460
Drug: Timolol/ FDC/ Placebo/ Tafluprost
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Prior timolol users: Timolol (administered at 08:00 and 20:00) or FDC of tafluprost and timolol (at 08:00) and Placebo eye drops (at 20:00).~Prior prostaglandin users: Tafluprost (administered at 08:00) or FDC of tafluprost and timolol (administered at 08:00).
Study: NCT00802529
Drug: Methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 transtympanic injections at interval of two weeks.
Study: NCT02882074
Drug: Human albumin
Normalized name: Human albumin
DrugBank: Albumin human (DB00062)
Approvals — FDA: no, EMA: no, PMDA: no
Description: human albumin 5% during surgery
Study: NCT02882074
Drug: Hydroxyethyl starch
Normalized name: Hydroxyethyl starch
DrugBank: Hydroxyethyl Starch (DB09106)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6% Hydroxyethyl starch 130/0.4 during surgery
Study: NCT01117051
Drug: prucalopride
Normalized name: PRUCALOPRIDE
DrugBank: Prucalopride (DB06480)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1 or 2 mg prucalopride once daily before breakfast
Study: NCT00673270
Drug: Fludrocortisone
Normalized name: Fludrocortisone
DrugBank: Fludrocortisone (DB00687)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 µg of fludrocortisone per os
Study: NCT00673270
Drug: Placebo of Fludrocortisone
DrugBank: Fludrocortisone (DB00687)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet of placebo of Fludrocortisone
Study: NCT00206076
Drug: mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: mycophenolate mofetil and half their baseline dose of calcineurin inhibitor
Study: NCT00206076
Drug: mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: mycophenolate mofetil monotherapy
Study: NCT02545231
Drug: Pitavastatin 1mg
Normalized name: PITAVASTATIN 1MG TAB
DrugBank: Pitavastatin (DB08860)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: To compare different doses of statins on atherosclerosis progression and neointimal hyperplasia
Study: NCT02545231
Drug: Pitavastatin 4mg
Normalized name: PITAVASTATIN 4MG TAB
DrugBank: Pitavastatin (DB08860)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: To compare different doses of statins on atherosclerosis progression and neointimal hyperplasia
Study: NCT04210219
Drug: JNJ-64264681
Normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-64264681 capsule will be administered orally.
Study: NCT02103361
Drug: Ustekinumab
Normalized name: Ustekinumab
DrugBank: Ustekinumab (DB05679)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02103361
Drug: Guselkumab
Normalized name: Guselkumab
DrugBank: Guselkumab (DB11834)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT03555578
Drug: Leuprorelin Acetate
Normalized name: Leuprorelin acetate
DrugBank: Leuprolide (DB00007)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Leuprorelin Acetate Injection Kit
Study: NCT00461331
Drug: Insulin Aspart
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Either one of these insulins were given to the patient as the second insulin (depending on which was given as the first one, the other insulin was insulin 2). Patients used this insulin in the same dose as they did prior to entering the study.
Study: NCT00461331
Drug: Insulin Lispro
Normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients were given either insulin Aspart or Lispro in test period 1. Then they were switched to the other insulin in test period 2.
Study: NCT00882401
Drug: Ergocalciferol (Vitamin D)
Normalized name: ERGOCALCIFEROL (VITAMIN D) 25000 UNT CAP
DrugBank: Ergocalciferol (DB00153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ergocalciferol: 50,000 IU per week for 1 month followed by 50,000 IU per month for 5 months.
Study: NCT00057681
Drug: Lithium carbonate
Normalized name: Lithium Carbonate
DrugBank: Lithium carbonate (DB14509)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Titrated until blood level is 1.1 to 1.3 mEq/L
Study: NCT00057681
Drug: Valproate
Normalized name: Valproate
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Titrated until blood level is 111 to 125 ug/mL
Study: NCT00159666
Drug: pregabalin
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01757366
Drug: Ginsenoside Rg3 plus First-line Chemotherapy
Normalized name: ginsenoside
DrugBank: Ginsenoside Rg3 (DB19257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginsenoside Rg3 20mg 2/day po,patients will receive Ginsenoside Rg3 until progression~XELOX(oxaliplatin 130mg/m2 iv d1;capecitabine 1000mg/m2 po bid d1-14)every 3 weeks for 4 cycles followed by capecitabine until progression
Study: NCT04921046
Drug: lignocaine
Normalized name: Lignocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: After giving lignocaine to a group of people, myoclonus was observed after the dose of etomidate given two minutes after lignocaine.
Study: NCT00057681
Drug: Risperidone
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Titrated by weight until dose is 2.0 mg BID to 3.0 mg BID
Study: NCT01751802
Drug: Ecopipam
Normalized name: Ecopipam
DrugBank: Ecopipam (DB12273)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antagonist of the dopamine D1 receptor
Study: NCT01759888
Drug: 18F-DTBZ
Normalized name: (18F)-Fluoride
DrugBank: Fluoride ion F-18 (DB09398)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive a single i.v. administration of approximately 10 mCi 18F-FP-(+)-DTBZ (10 nmole FP-(+)-DTBZ) immediately prior to each scan.~The proposed dose for this study is based on our phase I study. At the proposed human dose of 10 mCi, the whole body effective dose (ED) will be approximately 680 mrem. The estimated human ED is expected to be comparable to or below the range of other approved brain imaging agents, such as 18F-FDG.
Study: NCT04921046
Drug: Midazolam 1 milligram Prefilled Syringe
Normalized name: midazolam Prefilled Syringe
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: after giving midazolam to the second group of people two minutes before etomidate dose, myoclonus was observed for one minute.
Study: NCT03123848
Drug: Darunavir/Cobicistat
Normalized name: darunavir/cobicistat 800 mg-150 mg ORAL TABLET
DrugBank: Darunavir (DB01264)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive a FDC tablet of darunavir 800 mg and cobicistat 150 mg orally in the morning of Day 1.
Study: NCT02659930
Drug: pomalidomide
Normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: pomalidomide once a day, days 1-21 of a 28-day cycle, at the dose levels described in dose escalation plan
Study: NCT03889912
Drug: Cemiplimab
Normalized name: CEMIPLIMAB
DrugBank: Cemiplimab (DB14707)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Each patient will receive intralesional injections of cemiplimab every week (QW), or at less frequent dosing into the lesion at the assigned dose level for 3-12 weeks prior to scheduled surgery
Study: NCT01369355
Drug: Ustekinumab 90 mg SC q8w
Normalized name: ustekinumab 90 MG/ML
DrugBank: Ustekinumab (DB05679)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ustekinumab 90 mg will be administered subcutaneously every 8 weeks (q8w) through Week 40.
Study: NCT01369355
Drug: Ustekinumab 130 mg IV
DrugBank: Ustekinumab (DB05679)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ustekinumab 130 mg will be administered as a single intravenous infusion at week 0.
Study: NCT01369355
Drug: Ustekinumab 90 mg SC q12w
Normalized name: ustekinumab 90 MG/ML
DrugBank: Ustekinumab (DB05679)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ustekinumab 90 mg will be administered as subcutaneously every 12 weeks (q12w) through Week 40.
Study: NCT02319759
Drug: Guselkumab
Normalized name: Guselkumab
DrugBank: Guselkumab (DB11834)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: In the guselkumab group, Guselkumab 100 mg subcutaneous injection will be administered at Weeks 0, 4, 12, 20, 28, 36 and 44. In the placebo group, guselkumab 100 mg subcutaneous injection will be administered at Weeks 24, 28, 36 and 44 for participants remaining on placebo at Week 24.
Study: NCT02319759
Drug: Ustekinumab
Normalized name: Ustekinumab
DrugBank: Ustekinumab (DB05679)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: In both placebo and guselkumab groups, if the participants qualify for early escape, they will switch to receive ustekinumab 45 mg or 90 mg subcutaneous injection at Weeks 16, 20, 32, and 44 based on the approved dosage in the particular country of the study.
Study: NCT03131154
Drug: ADX-102 Ophthalmic Solution (0.5%)
Normalized name: ADX 102
DrugBank: Reproxalap (DB16688)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADX-102 Ophthalmic Solution (0.5%) administered for approximately four weeks.
Study: NCT03131154
Drug: Vehicle of ADX-102 Ophthalmic Solution
Normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle of ADX-102 Ophthalmic Solution administered for approximately four weeks.
Study: NCT00024167
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 75 mg/m2 intravenous piggyback (IVPB) over 1 hour, Day 1, every 3 weeks.
Study: NCT00024167
Drug: Estramustine phosphate sodium
Normalized name: Estramustine Phosphate Sodium
DrugBank: Estramustine (DB01196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 140 mg orally 3 x day, Days 1 through 7 on Weeks 2, 4, 6
Study: NCT00024167
Drug: Ketoconazole
Normalized name: Ketoconazole
DrugBank: Ketoconazole (DB01026)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 400 mg orally (po) 3 x day, Days 1 through 7
Study: NCT00024167
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 mg orally 2 x daily, weeks 1-14
Study: NCT00024167
Drug: Vinblastine
Normalized name: Vinblastine
DrugBank: Vinblastine (DB00570)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4 mg/m2 IVPB, Day 1 on Weeks 2, 4, 6
Study: NCT00024167
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 4 mg is given orally at 12 and 1 hours before and 12 hours after docetaxel.
Study: NCT03610399
Drug: Primaquine
Normalized name: Primaquine
DrugBank: Primaquine (DB01087)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Different total dose and supervision.
Study: NCT01936909
Drug: Anakinra (weeks 1-2)
Normalized name: anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Anakinra 100 mg daily for weeks 1 and 2
Study: NCT01936909
Drug: Anakinra (weeks 3-12)
Normalized name: anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02339064
Drug: apomorphine infusion
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment with apomorphine provided by continuous subcutaneous infusion using a portable external electronic pump device
Study: NCT00290979
Drug: insulin glulisine
Normalized name: Insulin Glulisine
DrugBank: Insulin glulisine (DB01309)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT06424236
Drug: Gantenerumab
Normalized name: Gantenerumab
DrugBank: Gantenerumab (DB12034)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open-label administered Subcutaneously every 4 weeks, at escalating doses; at target, dosing was every 2 weeks
Study: NCT04397263
Drug: Guselkumab
Normalized name: Guselkumab
DrugBank: Guselkumab (DB11834)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Guselkumab will be administered intravenously for the first 3 doses and then subcutaneously for the subsequent doses.
Study: NCT03565666
Drug: iLet Bionic Pancreas insulin-only configuration with Fiasp
Normalized name: insulin aspart, human Cartridge [Fiasp]
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: iLet Bionic Pancreas insulin-only configuration with Fiasp (faster insulin aspart)
Study: NCT04016142
Drug: Carboplatin-Paclitaxel adjuvant chemotherapy
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will receive a first part of treatment corresponding to a standard of care (standard concomitant radio-chemotherapy, Part 1 of the study).~Then, they will be included in the second part of the study for the second part of treatment (experimental adjuvant chemotherapy, Part 2 of the study), providing they fulfill eligibility criteria at this stage.~The second part consists in 4 cycles of Carboplatin-Paclitaxel adjuvant chemotherapy (one cycle = 3 weeks of treatment and 1 free-week)
Study: NCT04577352
Drug: Vatiquinone
Normalized name: Vatiquinone
DrugBank: Vatiquinone (DB11917)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vatiquinone will be administered per dose and schedule specified in the arm.
Study: NCT00300118
Drug: budesonide
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 9 mg
Study: NCT00300118
Drug: mesalazine
Normalized name: mesalazine
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4.5 g
Study: NCT02666703
Drug: Methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00033072
Drug: Selegiline
Normalized name: Selegiline
DrugBank: Selegiline (DB01037)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02162563
Drug: FOLFOXIRI with bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: FOLFOXIRI + bevacizumab Bevacizumab 5 mg/kg in 15-30 minutes i.v., followed by irinotecan 165 mg/m2 i.v. in 60 minutes, followed by oxaliplatin 85 mg/m2 i.v. together with leucovorin 400 mg/m2 i.v. in 120 minutes, followed by continuous infusion of 5-fluorouracil 3200 mg/m2 in 46 hours, every 2 weeks